Patterns of Progression on Osimertinib in EGFR T790M positive NSCLC: A Swiss Cohort Study

In recent years, multiple actionable oncogenic drivers and corresponding targeted agents have been identified in non-small-cell lung cancer (NSCLC) patients. In patients with activating epidermal growth factor receptor (EGFR) mutations improved outcomes with respect to response rate (ORR), progression-free survival (PFS), and quality of life were demonstrated with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in comparison to standard first line platinum-based chemotherapy [1 –6].

Source: Lung Cancer - February 19, 2019 Category: Cancer & Oncology Authors: S Schmid, D Klingbiel, S Aeppli, C Britschgi, O Gautschi, M Pless, S Rothschild, L Wannesson, W Janthur, D Foerbs, I Demmer, W Jochum, M Fr üh Source Type: research